Who We Are
Curae Pharma360 has significant experience in developing and commercializing the medicines people need.
Board of Directors
Autumn Ehnow
Chief Executive Officer of Curae Pharma360
Autumn Ehnow is the Chief Executive Officer of Curae Pharma360 and also serves as Executive Vice President, Policy & Strategic Market Access at Medicines360, the nonprofit parent company of Curae. Autumn’s two decades as a pharmaceutical and nonprofit leader, and personal experiences when needed medications were out of reach, have informed her drive and dedication to addressing the gap in equitable access to crucial medicines. With a strong track record of structuring and managing business partnerships in the U.S. and across the globe, and her role establishing the commercial operations at Curae, Autumn sets the strategy and guides plans to scale the organization. Autumn has spent 10 years at for-profit pharmaceutical companies and over 15 years in non-profit pharmaceutical entities with a history of leading successful partnerships with both governmental agencies and private pharmaceutical companies to develop new medicines for both small and large molecule products. At the Institute for OneWorld Health, she was integral in forming and managing the Bill and Melinda Gates Foundation grant and the multi-company partnership that brought semi-synthetic Artemisinin to market. As part of the original founding team of Medicines360, she helped define and lead the program strategy and implementation that brought the hormonal IUD to market in the USA, breaking down barriers to access in the process. She is a frequent presenter on health equity topics, and holds a BS in Molecular and Cellular Biology.
Jay Bapna
Board Chair
Jay Bapna is Board Chair of Curae Pharma360 Inc. For over 30 years, Mr. Bapna has leveraged his diverse experience in both generic and branded drug companies to help C-suite executives navigate a variety of complex issues. As Senior Vice President, Global Manufacturing at Allergan, a global pharmaceutical company, Mr. Bapna led a global network of manufacturing sites with 5,000+ employees that produced biologics, pharmaceuticals, and devices – generating $14B+ in annual revenue. He has led a range of complex projects with a total capital expense (CapEx) value of over $2B. He has also been involved in over $200B of M&A and restructuring activities.
As Chair of the Board of Curae, I have a deep commitment to put us at the forefront of prioritizing the availability and affordability of critical care for everyone. I am putting my diverse experience in both generic and branded drug companies to make sure Curae achieves its goal of putting people before profits.
Andrea Olariu, MD, PhD
Andrea Olariu, MD, PhD is the CEO of Medicines360 Inc., the nonprofit parent company of Curae. At Medicines360, she led the development, approval and indication expansion strategy of the company’s flagship product, a hormonal IUD that received FDA approval in 2015, followed by several approvals in global markets. Addressing the gap in equitable access to medicines is central to Andrea’s strategic approach to setting Curae’s overall direction. Before joining Medicines360, Andrea developed and implemented clinical and regulatory strategies for several medical devices that received approval in the U.S., Canada, and the European Union. Prior to moving to the United States, Dr. Olariu worked for over 15 years in academia, as an Associate Professor of Dermatology at the University of Szeged in Szeged, Hungary and a Senior Lecturer of Immunology at the University of Medicine and Pharmacy, Timisoara in Timisoara, Romania. Dr. Olariu has authored over 40 peer-reviewed medical publications, is the recipient of several academic honors, and has spoken at national and international conferences.
Roy Beveridge, MD
Dr. Roy Beveridge is a medical oncologist who has been in practice for more than 25 years. He is currently a Senior Advisor at Avalere, and most recently served as Humana’s Chief Medical Officer where he led clinical policy, population health and clinical quality initiatives. Dr. Beveridge has held similar roles for US Oncology and McKesson Specialty. Much of his recent work has focused on social determinants of health and improving the health of underserved populations. He has also published more than 200 papers.
As a physician, I am deeply committed to equitable health care access — it is the “why” behind my work at Curae. By ensuring there is a stable supply of critical drugs, we can help ensure people get the care they need, when they need it.
Mike Cunningham, Pharm.D.
Mike Cunningham is a strategic healthcare executive with expertise across diverse settings, including management roles in a large academic medical center pharmacy, business development in a venture-backed specialty distribution business, co-founding a specialty group purchasing organization, and serving as General Manager in a Fortune 100 pharmaceutical wholesaler. With an entrepreneurial mindset accompanied by experience managing multibillion-dollar contracts, he has addressed challenges surrounding new product launches, FDA approval, contracting strategies, reimbursement challenges, and building partnerships with new and established pharmaceutical companies.
Having spent over three decades in purchasing, GPO, and distribution leadership, I have seen the problems caused by product shortages and know what needs to be fixed. I am putting my expertise to work for Curae because of its steadfast commitment to its mission to increase access and affordability of products. We will strive to be the stable force in the American market that has been missing.